medigraphic.com
ISSN 1028-4818 (Electronic)

2015, Number 4

<< Back Next >>

Mul Med 2015; 19 (4)

Neutropenia like an adverse effect of the chemotherapeutic treatment in patients with cancer

Olivera FEM, Olivera FY, Caballero AI, López GY, Millán VMM

Language: Spanish
References: 24
Page: 1-12
PDF size: 271.89 Kb.


ABSTRACT

This research was performed with the objective to know the current aspects related to the presence of neutropenia as an unwanted effect of the use of chemotherapy in patients with oncoproliferative processes, as this event occurs in a significant number of them, and few receive active prophylaxis, favoring the emergence complications that worsen the prognosis, delay the treatment and even cause death. This research makes reference to a literature review of national and international experiences, some definitions and clinical-epidemiological approaches are discussed, plus several new treatment techniques. It was carried out a review of PubMed, LILACS and CUMED databases since 2010 to 2014; other resources were consulted on the Internet as web pages of institutions and associations of Biomedical Sciences. Both review and original articles were included. It was concluded that this decrease in neutrophils varies according to the individual characteristics of the patient, the type of treatment, and the stage of disease, for which there have been developed innovative techniques for its management, proving efficiency and safety in neutropenic patients.


REFERENCES

  1. 1- Anuario Estadístico [Internet]. La Habana: MINSAP; 2013 [Citado 2013 mayo 25]. Disponible en: http://www.infomed.sld.cu/anuario/anu13/indice.html

  2. 2- Aapro M, Crawford J, Kamioner D. Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? Support Care Cancer [Internet]. 2010 May [citado 1 de Julio de 2015]; 18(5):529-41. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/20191292

  3. 3- Smith tj, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factor: an evidence-based clinical practice guideline. J Clin Oncol [Internet]. 2006 [citado 1 de Julio de 2015]; 24(35):3187-3206. Disponible en: http://jco.ascopubs.org/content/24/19/3187.full

  4. 4- Agyeman P, Kontny U, Nadal D, Leibundgut K, Niggli F, Simon A, et al. A Prospective Multicenter SPOG 2003 FN Study of Microbiologically Defined Infections in Pediatric Cancer Patients with Fever and Neutropenia. Pediatr Infect Dis J [Internet]. 2014 [citado 2 de Julio de 2015]; 33(9):219-25. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/24618935

  5. 5- Pettengell R, Bosly A, Szucs TD, Jackisch C, Leonard R, Paridaens R, et al. Impact of Neutropenia in Chemotherapy-European Study Group (INC-EU). Multivariate analysis of febrile neutropenia occurrence in patients data from the INC-EU Prospective Observational European Neutropenia Study. Br J Haematol. 2009 Mar; 144(5):677-85.

  6. 6- Pagliuca A, Carrington pa, Pettengell r, Role S, Keidan J.Guidelines on the used of colony stimulating factor in hematological malignancies. BJH [Internet]. 2013 [citado 1 de Julio de 2015]; 123(1):22-33.Disponible en: http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.2003.04546.x/abstract

  7. 7- Sill RH. Practical algorithms in pediatric hematology and oncology. [s/l]: American Society of Hematology; 2013.

  8. 8- Van de Wetering MD, de Witte MA, Kremmer RC. Efficacy of oral prophylactic antibiotic in neutropenia afebril oncology patient: a systematic review of randomized controlled trial. Eur J Cancer [Internet]. 2005 [citado 1 de julio de 2015]; 41:1372-82. Disponible en: http://www.researchgate.net/profile/Martin_Offringa/publication/7827746_Efficacy_of_oral_prophylactic_antibiotics_in_neutropenic_afebrile_oncology_patients_a_systematic_review_of_randomised_controlled_trials/links/0deec517d4f95b5c25000000.pdf

  9. 9- Mayordomo JI, López A, Viñolas N, Castellanos J, Pernas S, Domingo Alonso J, et al. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain. Curr Med Res Opin [Internet]. 2009 Oct [citado 1 de Julio de 2015]; 25(10):2533-42.Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19722781

  10. 10- Gratwohl A, Baldomero H, Aljurf M. Hematopoietic stem cell transplantation: a global perspective. JAMA [Internet]. 2010 [citado 1 de julio de 2015]; 303(16): 1617–24. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/20424252

  11. 11- Maschmeyer G, Carratalà J, Buchheidt D, Hamprecht A, Heussel CP, Kahl C,et al. Diagnosis and Antimicrobial Therapy in Febrile Neutropenic Patients (allogeneic SCT excluded) Updated Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Oncol [Internet]. 2015 May 15 [citado 1 de Julio de 2015];26(1): 21- 33.

  12. 12- Danova M, Chiroli S, Rosti G, Doan QV. Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients. Tumori [Internet]. 2009 Mar-Apr [citado 1 de Julio de 2015]; 95(2):219-26. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19579869

  13. 13- National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Comprehensive Cancer Network [Internet]. 2012 [Citado 2013 abril 5].Disponible en: http://www.nccn.org/professionals/physician_gls/PDF/fever.pdf.

  14. 14- Danova M, Barni S, Mastro L del, Danesi R, Pappagallo GL.Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors. Expert Rev Anticancer Ther [Internet]. 2011 Aug [citado 2 de Julio de 2015]; 11(8):1303-13. Disponible en: http://informahealthcare.com/doi/abs/10.1586/era.11.72

  15. 15- Akimichi O, Atsushi K, Hitoshi O, Akira O, Akaru I,Koji O. Guidelines for safety management of granulocyte transfusion in Japan. Int J Hematol [Internet].2010 [citado 2 de Julio de 2015]; 91:201–8. Disponible en: http://mdanderson.influuent.utsystem.edu/en/publications/guidelines-for-safety-management-of-granulocyte-transfusion-in-japan%284928c4ed-f509-4eda-941b-87baa06a78a0%29.html

  16. 16- Naeim A, Henk HJ, Becker L, Chia V, Badre S, Li X. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). BMC Cancer. 2013 Jan 8; 13:11.

  17. 17- Lee S, Knox A, Zeng IS, Coomarasamy C, Blacklock H, Issa S. Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis. Support Care Cancer [Internet]. 2013 Mar [citado 3 de Julio de2015]; 21(3):841-6. Disponible en: http://download.springer.com/static/pdf/556/art%253A10.1007%252Fs00520-012-1589-2.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00520-012-1589-2&token2=exp=1435929251~acl=%2Fstatic%2Fpdf%2F556%2Fart%25253A10.1007%25252Fs00520-012-1589-2.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs00520-012-1589-2*~hmac=10053dc8dc70d8a25dc5fba71dd52810c21f1f5c56f9d8f900da8a1d458ac2ec

  18. 19- Suter C, Franzen D, Pestalozzi B. Fever and neutropenia. Praxis [Internet]. 2013 [citado 3 de Julio de2015]; 102(22):1341-50. Disponible en: http://www.pubfacts.com/detail/24169478/Fever-and-neutropenia

  19. 20- Saito H, Takahashi K, Okuno M, Saka H, Imaizumi K, Hasegawa Y,et al. Cefepime monotherapy for febrile neutropenia in patients with lung cancer. J Infect Chemother [Internet]. 2014 [citado 3 de Julio de 2015]; 20(6):365-9. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/24679653

  20. 21- Roohullah A, Moniwa A, Wood C, Humble M, Balm M, Carter J,et al. Imipenem versus piperacillin/tazobactam for empiric treatment of neutropenic fever in adults. Intern Med J. [Internet]. 2013 Oct [citado 3 de Julio de 2015]; 43(10):1151-4.Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/23800137

  21. 22- Perron T, Emara M, Ahmed S. Time to antibiotics and outcomes in cancer patients with febrile neutropenia. BMC Health Serv Res [Internet]. 2014 Apr 10 [citado 3 de Julio de 2015]; 14:162. Disponible en: http://www.biomedcentral.com/1472-6963/14/162

  22. 23- Rolston KV. Neutropenic Fever and sepsis: evaluation and management. Cancer Treat Res [Internet]. 2014 [citado 3 de Julio de 2015]; 161:181-202. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/24706225

  23. 24- Jørgensen KJ, Gøtzsche PC, Dalbøge CS, Johansen HK. Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia. Cochrane Database Syst Rev [Internet]. 2014 Feb 24 [citado 3 de Julio de 2015]; 2. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/24563222

  24. 25- Freyer G, Jovenin N, Yazbek G, Villanueva C, Hussain A, Berthune A, et al. Granulocyte-colony stimulating factor (G-CSF) has significant efficacy as secondary prophylaxis of chemotherapy-induced neutropenia in patients with solid tumors: results of a prospective study. Anticancer Res [Internet]. 2013 Jan [citado 3 de Julio de 2015]; 33(1):301-7. Disponible en: http://www.researchgate.net/publication/233984633_Granocyte-colony_Stimulating_Factor_%28G-CSF%29_Has_Significant_Efficacy_as_Secondary_Prophylaxis_of_Chemotherapy-induced_Neutropenia_in_Patients_with_Solid_Tumors_Results_of_a_Prospective_Study




2020     |     www.medigraphic.com